Cellular Biomedicine (NASDAQ:CBMG)‘s stock had its “buy” rating restated by B. Riley in a research note issued to investors on Friday, March 16th.
CBMG has been the subject of a number of other research reports. Maxim Group reaffirmed a “hold” rating on shares of Cellular Biomedicine in a research report on Tuesday, March 6th. BidaskClub raised Cellular Biomedicine from a “hold” rating to a “buy” rating in a research report on Wednesday, January 10th.
Shares of NASDAQ CBMG opened at $19.65 on Friday. The stock has a market capitalization of $340.35, a price-to-earnings ratio of -11.04 and a beta of 3.49. Cellular Biomedicine has a twelve month low of $5.05 and a twelve month high of $22.75.
Cellular Biomedicine (NASDAQ:CBMG) last posted its quarterly earnings data on Tuesday, March 6th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.08). Cellular Biomedicine had a negative return on equity of 45.60% and a negative net margin of 7,564.10%. The firm had revenue of $0.07 million during the quarter. equities analysts predict that Cellular Biomedicine will post -1.94 earnings per share for the current fiscal year.
A hedge fund recently bought a new stake in Cellular Biomedicine stock. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Cellular Biomedicine (NASDAQ:CBMG) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 10,041 shares of the biotechnology company’s stock, valued at approximately $107,000. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.07% of Cellular Biomedicine as of its most recent SEC filing. 2.79% of the stock is owned by institutional investors and hedge funds.
WARNING: “Cellular Biomedicine (CBMG) Stock Rating Reaffirmed by B. Riley” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/08/cellular-biomedicine-groups-cbmg-buy-rating-reiterated-at-b-riley.html.
About Cellular Biomedicine
Cellular Biomedicine Group Inc, a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases.
Receive News & Ratings for Cellular Biomedicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine and related companies with MarketBeat.com's FREE daily email newsletter.